Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edrecolomab and Sargramostim in 5-FU Resistant Colorectal Cancer
NCT00002664Phase 2Withdrawn
- Start
- Jul 1995
- Primary completion
- Feb 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of edrecolomab in colorectal cancer (CRC). Primary endpoints: Objective Response Rate, Duration of Response and 1 more. Planned start Jul 1995; status: withdrawn.
02
Drugs
edrecolomab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00002664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002664.